<DOC>
	<DOCNO>NCT00039351</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat old patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Older Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete remission ( CR ) rate duration CR frail elderly patient diffuse large B-cell peripheral T-cell non-Hodgkin 's lymphoma treat cyclophosphamide , vincristine , prednisone . - Determine time progression overall survival patient treat regimen . - Determine severe toxicity rate regimen patient . - Assess quality life patient treat regimen . OUTLINE : This multicenter study . Patients receive cyclophosphamide IV vincristine IV day 1 oral prednisone day 1-5 . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Patients stage I II non-Hodgkin 's lymphoma ( NHL ) , baseline lactate dehydrogenase ( LDH ) elevation , baseline WHO performance status 0-1 , long tumor diameter le 5 cm , achieve partial response ( PR ) complete response ( CR ) , receive 1 additional course chemotherapy . Patients undergo involved-field radiotherapy daily 5 day week 3.5-4 week . Patients stage I II NHL , baseline LDH elevation , and/or baseline WHO performance status 2-4 , and/or long tumor diameter least 5 cm , achieve PR CR , receive 3 additional course chemotherapy . Patients undergo involved-field radiotherapy daily 5 day week 3.5-4 week . Patients stage III IV NHL achieve CR PR receive 3 additional course chemotherapy . Patients undergo consolidative radiotherapy daily 5 day week 2.5-3 week . Quality life assess baseline , third chemotherapy course , end chemotherapy , every 6 month 3 year , annually thereafter . Patients follow every 3 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 29-56 patient accrue study within 12-18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large Bcell peripheral Tcell nonHodgkin 's lymphoma ( NHL ) No Burkitt'slike lymphoma Small cell bone marrow allow Previously untreated NHL At least 1 measurable lesion At least 1.1 cm Poor physiological status least 1 follow : WHO performance status 34 LVEF less 50 % Creatinine clearance le 50 mL/min Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Concurrent severe disease would preclude cyclophosphamide , vincristine , prednisolone , doxorubicin No cerebral meningeal involvement PATIENT CHARACTERISTICS : Age : 70 Performance status : See Disease Characteristics Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : See Disease Characteristics Other : HIV negative No malignancy within past 5 year except adequately treat basal cell skin cancer , curatively treat carcinoma situ cervix , curatively treat solid tumor No active infection No psychological , familial , sociological , geographical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : No concurrent investigational drug No concurrent antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
</DOC>